Tapering medication for paroxetine shortly available

20 October 2013   Twenty two prominent Dutch psychiatrists recommend the use of specially designed tapering medication for the cessation of treatment with paroxetine and venlafaxine. In the Dutch professional journal Tijdschrift voor Psychiatrie P. Groot et al.*) explain why the tapering of these antidepressants should be much more gradual than is currently possible with…

Change in board members

24 March 2013 Board member J.J. Fransen van de Putte, LLM, has resigned as of 12 February 2013. Cinderella is grateful for his contributions in accomplishing our mission and for his commitment to all aspects of our organization. Prof. Anton Hagebeek, haematologist-oncologist in Amsterdam and Utrecht, joined the board on 15 February.   Board member…

Collaboration between Cinderella Therapeutics and Dr. Huib Vriesendorp came to end.

18 Febr 2013 In recent weeks, fundamental differences of opinion have developed between the two founders of Cinderella, leading to a joint decision to go their separate ways. The collaboration between the Cinderella Therapeutics Foundation and Dr. Vriesendorp came to end on 15 February. Naturally this will have no effect on Cinderella’s mission and activities.

Radioimmunotherapy for brain and pancreas tumors has come to an end.

18 February 2013   Patients with a recurrence of the most aggressive brain tumor GBM (GlioBlastoma Multiforme) survive for just an average of 3 to 6 months following diagnosis. In Italy, in 1994, Dr. Riva was the first doctor to administer radioactively labeled IgG antibody against Tenascin C to patients with recurrent glioblastoma. An anti-Tenascin…

Tapering project.

29 January 2013 Cinderella plans to start a tapering project for Paroxetine.   Proposer: Harry Leurink, September 2010 Request and background information The idea was published in 2004 in a letter to the Dutch newspaper NRC Handelsblad and subsequently nominated for ‘Idea of the year’. A translation of this letter is provided below.

Anti-GD2 for the treatment of neuroblastoma.

15 January 2013 Progress report of project anti-GD2 mAb. Proposers: Peter Kapitein, following his visit in August 2010 to Richard O’Reilly, head of Pediatric Oncology at Memorial Sloan-Kettering Hospital (MSK) in New York; and the parents of a patient with neuroblastoma; entry no. 247 October 2010. Background This monoclonal antibody (mAb) improves survival in children with…

Ataluren project completed.

10 August 2012 The patients are receiving their medication again. Read about the court case, the reactions and our request for donations. Background information The case in court – the interlocutory proceedings- Full text of the verdict (in Dutch, English translation available upon request) Reactions by law experts and others in NRC.nl (in Dutch, English translation available upon request) Request…

Ataluren project: background information

09 August 2012   Ataluren The American company PTC Therapeutics has developed a drug that had originally been called PTC 124, but is now called Ataluren. It is intended for the treatment of hereditary diseases caused by so-called nonsense mutations. Such a nonsense mutation is present in a small part of patients with Duchenne’s disease…

On the galactosemia project

11 July 2012  An international consortium for research into galactosemia is being set up.   Request and background information In April 2010, a father whose children have galactosemia suggested that Cinderella develop a drug for this disorder. Galactosemia is an autosomal (not sex linked) recessive hereditary disorder with stepchild status. In Western Europe it occurs…

Projects

Cinderella is interested in compounds showing promise in preclinical research and phase-1 studies.
The efficacy and therapeutic ratio of these drugs will be demonstrated or disproved in a short period of time and in a small number of patients.

 

pumpkin